Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | Non-Final OA | Janssen Biotech, Inc. |
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | Non-Final OA | APEIRON THERAPEUTICS (HONG KONG) LTD. |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18182277 | ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER | Non-Final OA | The Regents of the University of California |
| 17327363 | TARGETED THERAPY FOR SMALL CELL LUNG CANCER | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17813100 | COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18324773 | Zwitterion Polymer-Drug Conjugates | Non-Final OA | University of Utah Research Foundation |
| 18185493 | ANG2-BINDING MOLECULES | Non-Final OA | Boehringer Ingelheim International GmBH |
| 18288375 | SINGLE DOMAIN PD-L1 ANTIBODIES | Non-Final OA | TJ BIOPHARMA (SHANGHAI) CO., LTD. |
| 18321354 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease | Non-Final OA | MacroGenics, Inc. |
| 17393253 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN | Final Rejection | CureVac AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy